Lowering PSA cutoffs to enhance detection of curable prostate cancer

Urology

Volumn 55, Issue 6, 2000, Pages 791-795

  Catalona, William J ^a   Ramos, Christian G ^b   Carvalhal, Gustavo F ^c   Yan, Yan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOSPITAL DEL TRABAJADOR   (Chile)

^c PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER TEST; DISEASE COURSE; HUMAN; MALE; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; SHORT SURVEY; UNITED STATES;

DISEASE PROGRESSION; HUMANS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0034077266     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00602-0     Document Type: Editorial

References (26)

1. B.F. Hankey E.J. Feuer L.X. Clegg Cancer surveillance series interpreting trends in prostate cancer. Part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates J Natl Cancer Inst 91 1999 1017 1024
2. W.J. Catalona D.S. Smith T.L. Ratliff Measurement of prostate-specific antigen in serum as a screening test for prostate cancer N Engl J Med 324 1991 1156 1161
3. D.S. Smith P.A. Humphrey W.J. Catalona The early detection of prostate carcinoma with prostate specific antigen the Washington University experience Cancer 80 1997 1852 1856
4. W.J. Catalona D.S. Smith T.L. Ratliff Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening JAMA 270 1993 948 954
5. W.J. Catalona J.P. Richie F.R. Ahmann Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer results of a multicenter clinical trial of 6,630 men J Urol 151 1994 1283 1290
6. H.B. Carter J.I. Epstein A.W. Partin Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease Urology 53 1999 126 130
7. S.H. Woolf Screening for prostate cancer with prostate-specific antigen N Engl J Med 333 1995 1401 1405
8. J.W. Colberg D.S. Smith W.J. Catalona Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4 ng/mL J Urol 149 1993 507 509
9. D.S. Smith W.J. Catalona J.C. Herschman Longitudinal screening for prostate cancer with prostate-specific antigen JAMA 276 1996 1309 1315
10. H.B. Carter J.I. Epstein D.W. Chan Recommended prostate-specific antigen testing intervals for the detection of curable prostate cancer JAMA 277 1997 1456 1460
11. P.H. Gann C.H. Hennekens M.J. Stampfer A prospective evaluation of plasma prostate-specific antigen for detection of prostate cancer JAMA 273 1995 289 294
12. F. Labrie A. Dupont R. Suburu Serum prostate specific antigen as pre-screening test for prostate cancer J Urol 147 1992 846 852
13. P.J. Littrup Prostate cancer screening—appropriate choices? Cancer Suppl 74 1994 2016 2022
14. W.J. Catalona D.S. Smith D.K. Ornstein Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4 ng/mL and benign prostate examination enhancement of specificity with free PSA measurements JAMA 277 1997 1452 1455
15. F.H. Schroder I. van der Cruijsen-Koeter H.J. de Koning Prostate cancer detection at low values of prostate specific antigen (PSA) J Urol 163 2000 806 811
16. J. Krumholtz G.F. Carvalhal C.G. Ramos Total PSA cutoff of 2.5 ng/mL correlates with favorable pathologic features of prostate cancer (abstract) J Urol 161 1999 99
17. J.A. Dugan D.G. Bostwick R.P. Myers The definition and preoperative prediction of clinically insignificant prostate cancer JAMA 275 1996 288 294
18. C.G. Ramos G.F. Carvalhal D.S. Smith Clinical and pathological characteristics and recurrence rates of stage T1c versus T2a or T2b prostate cancer J Urol 161 1999 1525 1529
19. J.I. Epstein P.C. Walsh M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368 374
20. R.J. Babaian P. Troncoso L.C. Steelhammer Tumor volume and prostate specific antigen implications for early detection and defining a window of curability J Urol 154 1995 1808 1812
21. W.J. Catalona A.W. Partin J.A. Finlay Use of percentage of free prostate- specific antigen to identify men at high risk of prostate cancer when PSA levels are 2 51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model Urology 54 1999 220 224
22. M.F. Darson A. Pacelli P. Roche Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases Urology 53 1999 939 944
23. M. Kwiatkowski F. Recker T. Piironen In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic “gray zone” of total PSA 4 to 10 ng/mL Urology 52 1998 360 365
24. A.W. Partin W.J. Catalona J.A. Finlay The use of human glandular kallikrein 2 (hK2) for the detection of prostate cancer preliminary analysis Urology 54 1999 839 845
25. D.S. Smith G.F. Carvalhal D.E. Mager Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men J Urol 160 1998 1734 1738
26. K. Kerlikowske D. Grady J. Barclay Positive predictive value of screening mammography by age and family history of breast cancer JAMA 270 1993 2444 2450